Focus:
Central Nervous System
-
29 May 2019 Analysis
World MS Day: applying disease-modifying drugs to PPMS
Ocrevus was the first disease modifying drugs approved for primary progressive MS, as well as relapsed forms of MS. After an initial hiccup with UK health regulators, Roche lowered the...
-
29 May 2019 Comment
Pricing of spinal muscular atrophy therapies crucial for expanded market access
It is arguable that limited treatment options for a rare disease such as spinal muscular atrophy means that approved therapies could launch at an exceptionally high price point.
-
23 May 2019 pressreleases
Natural, GMP and Pharma-Grade CBD Hits the Market
In 2017, CBDepot introduced a pharmaceutical good manufacturing practice (GMP) natural cannabinoid (CBD) isolate to the active pharmaceutical ingredients (API) segment during CPhI Frankfurt.
-
22 May 2019 Analysis
Dementia Action Week: the challenges of treating a multifaceted condition
Dementia refers to a large group of diseases that affect the brain. The most common form is Alzheimer’s, making it, unsurprisingly, the main target of pharma R&D. As these treatments...
-
21 May 2019 News
NIH awards T3D Therapeutics $9m to fund a trial of its lead product
US-based T3D Therapeutics has announced it has received a $9m grant over four years from the US National Institutes of Health (NIH)’s National Institute of Aging to support its Phase...
-
10 May 2019 News
BMS’ Opdivo fails in Phase III glioblastoma trial
Bristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial.
-
7 May 2019 whitepapers
Paracetamol Oral Suspension (120mg/5ml) Pharma Application Leaflet
Paracetamol suspension is used for the treatment of mild-to-moderate pain, including headaches, migraines, neuralgia, toothaches, sore throat and period pains.
-
7 May 2019 News
Bicycle and DDF collaborate on drug development for CNS conditions
UK-headquartered Bicycle Therapeutics and venture capital fund Dementia Discovery Fund (DDF) have entered into a collaboration to use the former’s bicyclic peptide technology to identify new targets and development novel...
-
7 May 2019 News
Skyhawk and Takeda partner to develop small molecule drugs
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases.
-
24 April 2019 News
Teva discontinues trial of Ajovy for episodic cluster headache
Israeli pharmaceutical company Teva has announced the discontinuation of its ENFORCE Phase III trial programme investigating the safety and efficacy of Ajovy (fremanezumab) for episodic cluster headaches.